Ping Wang, Ph.D.

Ping Wang, Ph.D.

	Ping Wang, Ph.D. Assistant Member The Methodist Hospital Research Institute Medical Director, Clinical Chemistry Laboratory Department of Pathology and Genomic Medicine The Methodist Hospital Physician Organization Assistant Professor of Pathology & Laboratory Medicine Weill Cornell Medical College of Cornell University Phone: 713-441-3294 Fax: 713-441-1565 E-mail: pwang@tmhs.org
Education B.S.   Biological Sciences and Biotech, Tsinghua University, Beijing, China Ph.D.   Molecular and Cellular Pharmacology, University of Wisconsin-Madison, Madison, WI Postdoctoral Training Postdoctoral Fellowship, Clinical Chemistry, University of California, San Francisco, CA

Biography

Dr. Ping Wang joined the Methodist Hospital as the Medical Director of Clinical Chemistry in 2007 after completing her postdoctoral fellowship in the laboratory of Dr. Alan Wu at the University of California, San Francisco. While a postdoctoral fellow, Dr. Wang studied the pharmacogenomics of the anticoagulant warfarin and created and tested a dosing algorithm for personalized dose management. Natural variation in the genes encoding vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) affect how an individual responds to warfarin. Dr. Wang's algorithm takes into account allelic variation in these two genes, therefore allowing the correct dose to be administered to each individual. Dr. Wang's research also included diagnostic method development using LC-MS/MS and targeted genotyping microarrays. In 2006, Dr. Wang was awarded the prestigious Paul E. Strandjord Young Investigator Award presented by the Academy of Clinical Laboratory Physicians and Scientists for her postdoctoral research.

Description of Research

Dr. Wang's current research focuses on the development of a personalized pharmacogenomics-based algorithm that can be used clinically to achieve fast and accurate tacrolimus dosing in renal transplant recipients. She is also engaged in studying pharmacogenomics of other drugs with low therapeutic indices, with the goal of implementing personalized drug dosing in clinical practice. Analysis and quantitation of drugs and biomarkers using mass spectrometry is another focus of her research.

Major Areas of Research

Pharmacogenomics, personalized medicine, diagnostic methods, mass spectrometry

Recent Publications

Wang P, Mao Y, Moses S, Patel S, Elliott E, Razo J, Zhou X, Wong STC, Shea E, Wu AHB, Gaber AO. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010, in press

Wang P, Molina CP, Maldonado JE, Bernard DW. In utero drugs of abuse exposure testing for newborn twins. J Clin Pathol. 2010 Mar;63(3):259-61.

Wang P, Huang L, Davis JL, Swartzman A, Roth B, Stone J, Wu AH. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta. 2008 Oct;396(1-2):86-8.